ARCT
Price
$7.21
Change
+$0.04 (+0.56%)
Updated
Feb 13 closing price
Capitalization
204.87M
16 days until earnings call
Intraday BUY SELL Signals
CDXS
Price
$1.20
Change
+$0.02 (+1.69%)
Updated
Feb 13 closing price
Capitalization
108.39M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs CDXS

Header iconARCT vs CDXS Comparison
Open Charts ARCT vs CDXSBanner chart's image
Arcturus Therapeutics Holdings
Price$7.21
Change+$0.04 (+0.56%)
Volume$318.65K
Capitalization204.87M
Codexis
Price$1.20
Change+$0.02 (+1.69%)
Volume$1.38M
Capitalization108.39M
ARCT vs CDXS Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. CDXS commentary
Feb 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 15, 2026
Stock price -- (ARCT: $7.21 vs. CDXS: $1.20)
Brand notoriety: ARCT and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 59% vs. CDXS: 127%
Market capitalization -- ARCT: $204.87M vs. CDXS: $108.39M
ARCT [@Biotechnology] is valued at $204.87M. CDXS’s [@Biotechnology] market capitalization is $108.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $124.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 1 green, 4 red.
According to our system of comparison, CDXS is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • CDXS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than CDXS.

Price Growth

ARCT (@Biotechnology) experienced а -4.76% price change this week, while CDXS (@Biotechnology) price change was -9.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.41%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +22.89%.

Reported Earning Dates

ARCT is expected to report earnings on Mar 02, 2026.

CDXS is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+2.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($205M) has a higher market cap than CDXS($108M). ARCT YTD gains are higher at: 17.618 vs. CDXS (-26.380). CDXS has higher annual earnings (EBITDA): -55.32M vs. ARCT (-60.46M). ARCT has more cash in the bank: 180M vs. CDXS (58.7M). ARCT has less debt than CDXS: ARCT (26M) vs CDXS (68.6M). ARCT has higher revenues than CDXS: ARCT (85.1M) vs CDXS (52.9M).
ARCTCDXSARCT / CDXS
Capitalization205M108M190%
EBITDA-60.46M-55.32M109%
Gain YTD17.618-26.380-67%
P/E RatioN/AN/A-
Revenue85.1M52.9M161%
Total Cash180M58.7M307%
Total Debt26M68.6M38%
FUNDAMENTALS RATINGS
ARCT vs CDXS: Fundamental Ratings
ARCT
CDXS
OUTLOOK RATING
1..100
6454
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
8393
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (27) in the Chemicals Specialty industry is in the same range as ARCT (58) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to ARCT’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that ARCT’s stock grew similarly to CDXS’s over the last 12 months.

ARCT's Price Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as CDXS (93) in the Chemicals Specialty industry. This means that ARCT’s stock grew similarly to CDXS’s over the last 12 months.

ARCT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that ARCT’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCDXS
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 24 days ago
79%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
CDXS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XONI0.060.01
+19.76%
Xtreme One Entertainment, Inc.
AKEJF34.00N/A
N/A
Ariake Japan
RMYHY6.26N/A
N/A
Ramsay Health Care Ltd.
QUCT2140.00N/A
N/A
Queen City Investments, Inc.
FANUY21.25-0.20
-0.93%
Fanuc Corporation

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been closely correlated with ARTV. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARCT jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+0.56%
ARTV - ARCT
80%
Closely correlated
+0.25%
VTGN - ARCT
80%
Closely correlated
-7.23%
TPST - ARCT
79%
Closely correlated
+2.16%
RZLT - ARCT
78%
Closely correlated
+5.79%
MREO - ARCT
78%
Closely correlated
-4.32%
More

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been closely correlated with ARTV. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDXS jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.69%
ARTV - CDXS
70%
Closely correlated
+0.25%
VTGN - CDXS
68%
Closely correlated
-7.23%
LENZ - CDXS
68%
Closely correlated
-0.69%
BCAB - CDXS
67%
Closely correlated
-8.93%
ARCT - CDXS
67%
Closely correlated
+0.56%
More